Key Takeaways
- • Contraline closed a $92.5 million Series B financing round co-led by BVF Partners L.P. and RA Capital Management, with participation from GV, Lumira Ventures, Invus, and other investors, positioning the company for late-stage clinical development of its lead male contraceptive asset.
- • NES/T Gel, a once-daily topical male contraceptive combining segesterone acetate (Nestorone®) and testosterone, completed a Phase 2b trial of 462 couples demonstrating efficacy, tolerability, reversibility, and user acceptability; Phase 3 development is anticipated to begin in 2027.
- • The compound addresses a substantial addressable market, with survey data indicating over 40 million men in the United States would consider using a novel male contraceptive, signaling meaningful commercial opportunity in underserved male reproductive health.
- • Iris van Alderwerelt van Rosenburgh, Ph.D., of BVF Partners L.P. joins Contraline's Board of Directors as part of the financing, reinforcing investor commitment and governance involvement in the company's development trajectory.
- • Contraline holds exclusive worldwide rights to NES/T, which was originally developed by the Population Council in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), providing a validated scientific foundation and de-risked intellectual property position.
Summary
Contraline, a clinical-stage biopharmaceutical company focused on novel male contraceptive development, announced the closing of a $92.5 million Series B financing round on June 2, 2026. The round was co-led by BVF Partners L.P. and RA Capital Management, with contributions from existing and new investors including GV, Lumira Ventures, and Invus. The capital infusion will support the advancement of NES/T Gel into late-stage clinical development and accelerate other pipeline programs within the company's male reproductive health portfolio.
NES/T Gel is positioned as a once-daily topical hormonal contraceptive that combines the synthetic progestin segesterone acetate (Nestorone®) with testosterone. The mechanism is designed to suppress sperm production while maintaining physiological testosterone levels, addressing a critical gap in male contraceptive options. The compound has completed a global Phase 2b clinical trial involving 462 couples, which demonstrated encouraging results across efficacy, tolerability, reversibility, and user acceptability metrics. The company plans to initiate Phase 3 clinical development in 2027, a timeline that aligns with the capital deployment strategy outlined in this financing round.
The market opportunity for male contraceptive innovation is substantial. Contraline's survey data indicate that more than 40 million men in the United States would consider adopting a novel male contraceptive, suggesting meaningful commercial potential in a historically underserved demographic. This data point carries particular relevance for institutional investors evaluating the company's long-term revenue prospects and market penetration assumptions.
NES/T was originally developed by the Population Council in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the U.S. National Institutes of Health. Contraline's acquisition of exclusive worldwide development and commercialization rights provides a de-risked intellectual property foundation and validates the scientific credibility of the program. As part of the Series B closing, Iris van Alderwerelt van Rosenburgh, Ph.D., of BVF Partners L.P. joined Contraline's Board of Directors, reflecting investor confidence and anticipated active board-level involvement in governance and strategic oversight during the critical late-stage development phase.
NES/T Gel is positioned as a once-daily topical hormonal contraceptive that combines the synthetic progestin segesterone acetate (Nestorone®) with testosterone. The mechanism is designed to suppress sperm production while maintaining physiological testosterone levels, addressing a critical gap in male contraceptive options. The compound has completed a global Phase 2b clinical trial involving 462 couples, which demonstrated encouraging results across efficacy, tolerability, reversibility, and user acceptability metrics. The company plans to initiate Phase 3 clinical development in 2027, a timeline that aligns with the capital deployment strategy outlined in this financing round.
The market opportunity for male contraceptive innovation is substantial. Contraline's survey data indicate that more than 40 million men in the United States would consider adopting a novel male contraceptive, suggesting meaningful commercial potential in a historically underserved demographic. This data point carries particular relevance for institutional investors evaluating the company's long-term revenue prospects and market penetration assumptions.
NES/T was originally developed by the Population Council in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the U.S. National Institutes of Health. Contraline's acquisition of exclusive worldwide development and commercialization rights provides a de-risked intellectual property foundation and validates the scientific credibility of the program. As part of the Series B closing, Iris van Alderwerelt van Rosenburgh, Ph.D., of BVF Partners L.P. joined Contraline's Board of Directors, reflecting investor confidence and anticipated active board-level involvement in governance and strategic oversight during the critical late-stage development phase.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.